Business Wire

TX-FLUENCE

26.5.2020 12:02:04 CEST | Business Wire | Press release

Share
Fluence Broad Spectrum LED Lighting Selected for New High-Tech Quarantine Greenhouse in the Netherlands

Fluence by OSRAM (Fluence) has been selected by Wageningen University & Research (WUR) as the lighting provider for Serre Red, the university’s new, high-tech quarantine greenhouse. Serre Red will be used for critical research on plant diseases—caused by viruses, bacteria, fungi and parasitic nematodes—including quarantine pathogens, as well as research on genetically modified organisms.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200526005096/en/

Built by Bosman van Zaal, Serre Red is one of the most advanced quarantine research facilities constructed to date. It features 63 compartments, ranging from 15 to 52 square meters with individual climate control, air filtering and access locks. Extensive technical equipment has been installed in a corridor sunk below ground level to avoid excess shade. Other features of the fully electric greenhouse include insulated double glazing, external shading, heat/cold storage and autoclaving, which sterilizes all materials including water and waste before leaving the greenhouse.

Broad spectrum lighting: Choosing LED over HPS

To reduce the influence of artificial light on their experiments, WUR’s researchers required broad spectrum lighting. Unifarm, the university’s greenhouse and field research facility, ran a market consultation during November and December 2019, then selected four manufacturers from a tender in January 2020. Fluence was granted the order in April after the four potential solutions were examined by WUR’s scientific committee.

“Traditionally, our greenhouses are equipped with HPS lighting,” said Dolf Straathof, head of Unifarm. “As we want to eliminate any influences that artificial lighting could have on experiments, we looked for a solution that came closest to the spectrum that our scientific team specified as optimal.”

“Fluence was one of those consulted, and they proposed higher light levels than we initially specified, which concurred with recommendations from our researchers,” Straathof continued. “The PhysioSpec® solution that Fluence proposed also fit our spectral requirements. In the end, Fluence offered us the best possible solution and exceeded our requirements for uniformity, offering the highest uniformity for a mix of low and tall crops throughout all compartments.”

Optimizing light levels and uniformity

Each compartment will have individual lighting controls, linked to the Hoogendoorn climate control system.

“This is the first time WUR has chosen LED, and specifically broad spectrum LED, as their standard lighting solution for a research greenhouse at Unifarm,” said Theo Tekstra, Fluence’s technical director in Europe, the Middle East and Africa and lead for the project’s design and implementation. “LED solutions have the added advantage that they can be controlled without change in spectrum or loss of efficiency, offering constant light levels and optimal daily light integral. By using our compact VYPR 2x2 full spectrum LED fixtures with the new compact PSU drivers and VYPR reflectors, we minimize shading and optimize overall uniformity. We are extremely proud that our solution was selected as the best in the tender and that we were awarded the contract for this prestigious project.”

Critical research for the world’s growers

Fluence supports, sponsors and collaborates on horticultural research projects throughout the world, including its membership in the Wageningen Research Club of 100—part of the WUR Business Unit for Greenhouse Horticulture in Bleiswijk.

The spread of viral infections—such as the tomato brown rugose fruit virus (ToBRFV)—remains a top concern for growers throughout the world. The new Serre Red facility enables WUR to expand and intensify its research capabilities, maintaining its position as a world leader in research on horticultural crop pathogens.

“ToBRFV currently threatens tomato, bell pepper and chili pepper crops throughout the globe, causing most production greenhouses to close to visitors and creating increased costs for growers through extensive disinfection and other precautionary measures,” said Dr. Theoharis Ouzounis, horticultural scientist at Fluence. “There is no treatment other than prevention and pervasive damage has been reported globally. Research into prevention and treatment of viral diseases is extremely important to safeguard our food production.”

For more information about Fluence lighting solutions, visit www.fluence.science .

About Fluence by OSRAM

Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates the most powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, The Netherlands. For more information about Fluence, visit www.fluence.science .

Link to high resolution pictures: www.fluence.science/press-links

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release

- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 14:00:00 CET | Press release

A domain-trained AI agent workforce enables production-scale AI across regulated financial institution operations Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye